tobevibart + peginterferon alfa

**Tobevibart + peginterferon alfa** is an experimental combination therapy, presumed to include the investigational monoclonal antibody tobevibart with peginterferon alfa, a long-acting form of recombinant interferon alpha. Peginterferon alfa is a pegylated protein that binds and activates type 1 interferon receptors, activating the JAK/STAT pathway and inducing an antiviral state, mainly used historically in hepatitis B and C treatment[1][4]. Tobevibart is a monoclonal antibody in development, but detailed mechanism of action and target are not available in the current search. The combination could potentially be used synergistically as an antiviral or immunotherapy, though specific indications and clinical data for this combination are not found in current public sources.